CALT News and Press, Calliditas Therapeutics AB From 07/20/23

2023-07-20 18:36:07 ET Summary We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales. Despite promising interim data, the market has y...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM , July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Cal...

2023-06-25 05:45:00 ET Summary AstraZeneca may separate its China operations into a standalone company and conduct an IPO in Hong Kong or Shanghai to protect its business from east-west political tensions. Cutia Therapeutics, a Shanghai dermatology company, raised $65 million in a...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM , June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

2023-05-31 12:07:41 ET Summary Shares of Calliditas Therapeutics plunged after the company missed Q1 revenue estimates. The quarter was better than it looks and the company saw record new patient enrollments for Tarpeyo. It was also too early for the recently reported 2-year e...

2023-05-30 06:54:18 ET Summary Patient and Prescriber Uptick: Despite Q1 2023's slightly disappointing earnings, Tarpeyo saw robust growth in new patient enrollments and prescriber numbers. Competitive Edge: Recent Phase 3 DUPLEX FSGS readout from Travere showing non-stat signific...

2023-05-16 18:55:18 ET Summary HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023. Solid Financi...

2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...

Calliditas Therapeutics: Interim Report Q1, 2023 PR Newswire STOCKHOLM , May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its prim...

2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...